Harnessing the potential of CRISPR-based platforms to advance the field of hospital medicine. Review uri icon

Overview

abstract

  • INTRODUCTION: Clustered regularly interspaced short palindromic repeats (CRISPR) are segments of nucleic acid that play a role in prokaryotic defense and form the basis of a genome editing technology that allows permanent alteration of genetic material. This methodology, known as CRISPR-Cas9, is poised to revolutionize molecular biology, but no literature yet exists on how these advances will affect hospitalists. AREAS COVERED: These specialists in inpatient medicine care for a wide variety of hospitalized patients, including those with infectious disease, cancer, cardiovascular disease, autoimmune disease, hematologic disease, and a variety of other conditions that may soon be impacted by advances in gene-modifying technology provided by CRISPR-Cas9. A Literature search was performed using PubMed [1 December 2019-17 April 2020]. EXPERT OPINION: This paper reviews the remarkable diagnostic and therapeutic potential of the CRISPR-Cas9 platform and concludes with a look at ethical issues and technical hurdles pertaining to the implementation of permanent gene modification in the practice of Hospital Medicine.

publication date

  • May 4, 2020

Research

keywords

  • CRISPR-Cas Systems
  • Genetic Therapy
  • Hospital Medicine

Identity

PubMed Central ID

  • PMC7212535

Scopus Document Identifier

  • 85087874884

Digital Object Identifier (DOI)

  • 10.1080/14787210.2020.1761333

PubMed ID

  • 32366131

Additional Document Info

volume

  • 18

issue

  • 8